Commodore Capital LP Acquires Shares of 11,445,000 Palisade Bio, Inc. $PALI

Commodore Capital LP acquired a new stake in Palisade Bio, Inc. (NASDAQ:PALI) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 11,445,000 shares of the company’s stock, valued at approximately $26,896,000. Palisade Bio makes up approximately 1.8% of Commodore Capital LP’s holdings, making the stock its 22nd largest position. Commodore Capital LP owned about 0.08% of Palisade Bio at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. BIT Capital GmbH purchased a new position in Palisade Bio in the fourth quarter valued at $717,000. B Group Inc. purchased a new position in Palisade Bio in the fourth quarter valued at $10,575,000. Persistent Asset Partners Ltd purchased a new position in Palisade Bio in the fourth quarter valued at $978,000. Platinum Investment Management Ltd. purchased a new position in Palisade Bio in the fourth quarter valued at $1,561,000. Finally, Jefferies Financial Group Inc. purchased a new position in Palisade Bio in the fourth quarter valued at $110,000. Hedge funds and other institutional investors own 11.79% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on PALI shares. Weiss Ratings cut shares of Palisade Bio from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 9th. Wolfe Research started coverage on shares of Palisade Bio in a report on Thursday, April 9th. They issued an “outperform” rating and a $7.00 price objective for the company. Wall Street Zen raised shares of Palisade Bio from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Stifel Nicolaus initiated coverage on shares of Palisade Bio in a report on Wednesday, February 25th. They issued a “buy” rating and a $5.00 price objective for the company. Finally, HC Wainwright initiated coverage on shares of Palisade Bio in a research report on Thursday, March 26th. They issued a “buy” rating and a $7.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $10.20.

Palisade Bio Stock Down 1.1%

PALI stock opened at $1.76 on Thursday. The stock has a market capitalization of $305.50 million, a P/E ratio of -1.74 and a beta of 1.52. The firm has a 50-day simple moving average of $1.97 and a 200-day simple moving average of $1.90. Palisade Bio, Inc. has a 52 week low of $0.53 and a 52 week high of $2.86.

Palisade Bio (NASDAQ:PALI) last released its earnings results on Tuesday, May 12th. The company reported ($0.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). On average, analysts expect that Palisade Bio, Inc. will post -0.21 earnings per share for the current year.

About Palisade Bio

Palisade Bio, Inc is a clinical?stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll?like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.